Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment
Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. Observations: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal de...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-03-01
|
| Series: | American Journal of Ophthalmology Case Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993622005357 |
| _version_ | 1797904320972193792 |
|---|---|
| author | Mohamad El Wardani Marc D. de Smet |
| author_facet | Mohamad El Wardani Marc D. de Smet |
| author_sort | Mohamad El Wardani |
| collection | DOAJ |
| description | Purpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. Observations: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. Conclusions and importance: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery. |
| first_indexed | 2024-04-10T09:47:04Z |
| format | Article |
| id | doaj.art-e903d8d3156e401e9e35789b6fdf0baa |
| institution | Directory Open Access Journal |
| issn | 2451-9936 |
| language | English |
| last_indexed | 2024-04-10T09:47:04Z |
| publishDate | 2023-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | American Journal of Ophthalmology Case Reports |
| spelling | doaj.art-e903d8d3156e401e9e35789b6fdf0baa2023-02-17T04:55:12ZengElsevierAmerican Journal of Ophthalmology Case Reports2451-99362023-03-0129101789Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachmentMohamad El Wardani0Marc D. de Smet1Helvetia Retina Associates, Micro Invasive Ocular Surgery Center, Av du Léman 32, Lausanne, Switzerland; CNVO Eye Centre, Rle Vautier 10, 1400, Yverdon-les-Bains, Switzerland; Corresponding author. Micro Invasive Ocular Surgery Center, Av du Léman 32, Lausanne, Switzerland.Helvetia Retina Associates, Micro Invasive Ocular Surgery Center, Av du Léman 32, Lausanne, SwitzerlandPurpose: To report the resolution of subretinal fluid persisting more than a year following retinal detachment surgery resolving with a short term course of mineralocorticoid receptor antagonists use. Observations: A 41 year-old, highly myopic male presented with a temporal rhegmatogenous retinal detachment involving the macula. The tear was treated with a radial sponge without subretinal fluid (SRF) drainage. Post-operatively, SRF persisted for more than 1 year with only slight improvement in visual acuity. On OCT, slow regression of subretinal fluid was noted. In order to stimulate the RPE pump, a systemic mineralocorticoid receptor antagonist (spironolactone 50 mg) was initiated after discussion with the patient. After one month of therapy, there was a complete resolution of SRF and the visual acuity improved. Two years later, there was no reaccumulation of SRF and the visual acuity remained stable. Conclusions and importance: A short term of course of mineralocorticoid receptor antagonist is a potential treatment for persistent subretinal fluid following a successful detachment surgery.http://www.sciencedirect.com/science/article/pii/S2451993622005357Retinal detachmentRetinal surgeryMineralocorticoid receptor antagonistSpironolactone |
| spellingShingle | Mohamad El Wardani Marc D. de Smet Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment American Journal of Ophthalmology Case Reports Retinal detachment Retinal surgery Mineralocorticoid receptor antagonist Spironolactone |
| title | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| title_full | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| title_fullStr | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| title_full_unstemmed | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| title_short | Mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| title_sort | mineralocorticoid receptor antagonists as a potential treatment option in persistent subretinal fluid following the repair of a rhegmatogenous retinal detachment |
| topic | Retinal detachment Retinal surgery Mineralocorticoid receptor antagonist Spironolactone |
| url | http://www.sciencedirect.com/science/article/pii/S2451993622005357 |
| work_keys_str_mv | AT mohamadelwardani mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment AT marcddesmet mineralocorticoidreceptorantagonistsasapotentialtreatmentoptioninpersistentsubretinalfluidfollowingtherepairofarhegmatogenousretinaldetachment |